Company Overview and News

5
Cytori's Chemotherapy Candidate Gets Orphan Drug Status

2018-09-18 zacks
Cytori Therapeutics (CYTX - Free Report) announced that the FDA has granted Orphan Drug designation to its chemotherapy candidate, ATI-1123, for the treatment of small cell lung cancer (“SCLC”).
CYTXW CYTX LGNZZ MDPEB LGND LGNYZ CTYX LGNXZ MDP ILMN LGNDZ

 
Phase 2 Ready Oncology Drug Receives FDA Orphan Drug Designation

2018-09-17 globenewswire
SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced that it received FDA orphan drug designation for its ATI-1123 chemotherapy drug product candidate, an albumin-stabilized pegylated liposomal docetaxel, for the treatment of small cell lung cancer.
CYTXW CYTX CTYX

 
Cytori Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-31 globenewswire
SAN DIEGO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it will present at the 20th Annual Rodman & Renshaw Global Investment Conference at 09:10 AM Eastern Time on Thursday, September 6, 2018. The presentation will take place in the Fontainebleau Foyer room at the St. Regis New York, in New York, NY. Dr. Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments.
CYTXW CYTX CTYX

 
Cytori Therapeutics Inc (CYTX) CEO Marc Hedrick on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics Second Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for your questions following the presentation. [Operator Instructions]
CYTXW CYTX CTYX

1
Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring

2018-08-09 globenewswire - 1
SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of “Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report.” This report describes preliminary data from the CELLCORDES trial of Cytori Cell Therapy™ (ADRCs) in patients with severe voice dysfunction due to scarring of the vocal fold (vocal cords).
CYTXW CYTX CTYX

1
SNEY / Sunergy, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-20 fintel.io - 1
Sunergy, Inc. (OTC:SNEY) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Sunergy, Inc. (OTC:SNEY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
CYTXW CYTX SNEY CTYX

3
GAHC / Global Arena Holding, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-20 fintel.io
Global Arena Holding, Inc. (OTC:GAHC) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Global Arena Holding, Inc. (OTC:GAHC) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
CYTXW CYTX GAHC CTYX

 
TFLG / Trafalgar Resources, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-20 fintel.io
Trafalgar Resources, Inc. (OTC:TFLG) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Trafalgar Resources, Inc. (OTC:TFLG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
CYTXW CYTX TFLG CTYX

2
PRVB / Provention Bio, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-20 fintel.io - 2
Provention Bio, Inc. (NASDAQ:PRVB) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Provention Bio, Inc. (NASDAQ:PRVB) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
CYTXW CYTX CTYX PRVB

2
KDP / Keurig Dr Pepper Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-19 fintel.io
Keurig Dr Pepper Inc. (NYSE:KDP) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Keurig Dr Pepper Inc. (NYSE:KDP) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
CYTXW CYTX KDP CTYX GMCR

 
ALGR / Allegro Merger Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-19 fintel.io
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
CYTXW CYTX CTYX ALGRU ALGR

 
RLM / Realm Therapeutics plc - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-19 fintel.io
Realm Therapeutics plc (NASDAQ:RLM) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Realm Therapeutics plc (NASDAQ:RLM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
CYTXW CYTX CTYX RLM

1
WSTI / WindStream Technologies, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-18 fintel.io - 1
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
WSTI CYTXW CYTX CTYX

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CYTX / Cytori Therapeutics, Inc. on message board site Silicon Investor.

Cytori Therapeutics, Inc. Cytori Therapeutics, Inc. Cytori Therapeutics, Inc.
CUSIP: 23283K105